Synthesis and pharmacological evaluation of pomalidomide derivatives useful for sickle cell disease treatment.
Synthesis and pharmacological evaluation of pomalidomide derivatives useful for sickle cell disease treatment.
复制标题
用于镰状细胞病治疗的泊马度胺衍生物的合成和药理学评价。
DOI:
10.1016/j.bioorg.2021.105077
复制
发表时间:
2021-09
影响因子:
5.1
通讯作者:
Dos Santos JL
中科院分区:
文献类型:
--
作者:
de Melo TRF;Dulmovits BM;Fernandes GFDS;de Souza CM;Lanaro C;He M;Al Abed Y;Chung MC;Blanc L;Costa FF;Dos Santos JL
Fetal hemoglobin (HbF) induction constitutes a valuable and validated approach to treat the symptoms of sickle cell disease (SCD). Here, we synthesized pomalidomide–nitric oxide (NO) donor derivatives (3a–f) and evaluated their suitability as novel HbF inducers. All compounds demonstrated different capacities of releasing NO, ranging 0.3–30.3%. Compound 3d was the most effective HbF inducer for CD34+ cells, exhibiting an effect similar to that of hydroxyurea. We investigated the mode of action of compound 3d for HbF induction by studying the in vitro alterations in the levels of transcription factors (BCL11A, IKAROS, and LRF), inhibition of histone deacetylase enzymes (HDAC-1 and HDAC-2), and measurement of cGMP levels. Additionally, compound 3d exhibited a potent anti-inflammatory effect similar to that of pomalidomide by reducing the TNF-α levels in human mononuclear cells treated with lipopolysaccharides up to 58.6%. Chemical hydrolysis studies revealed that compound 3d was stable at pH 7.4 up to 24 h. These results suggest that compound 3d is a novel HbF inducer prototype with the potential to treat SCD symptoms.
登录
查看更多内容
影响因子:
4.8
作者:
Browning, DD;Windes, ND;Ye, RD
通讯作者:
Ye, RD
影响因子:
20.3
作者:
Dijon, Marilyne;Bardin, Florence;Tonnelle, Cecile
通讯作者:
Tonnelle, Cecile
影响因子:
3.5
作者:
Cupertino da Silva, Yolanda Karla;Augusto, Cristina Villarinho;Alexandre-Moreira, Magna Suzana
通讯作者:
Alexandre-Moreira, Magna Suzana
影响因子:
6.5
作者:
Conran, N;Oresco-Santos, C;Costa, FF
通讯作者:
Costa, FF
影响因子:
5.6
作者:
Blanco, Fernando;Egan, Billy;Lloyd, David G.
通讯作者:
Lloyd, David G.